Zogenix, Inc. clinical trials

Acquired by UCB S.A., Mar 7, 2022 · source ↗

The registry lists 19 studies whose lead sponsor is Zogenix, Inc.. 0 are recruiting or about to start. Per ClinicalTrials.gov, last updated Jun 8, 2026.

Before and after it joined UCB S.A.

First submitted before Zogenix, Inc. became part of UCB S.A.: 19
First submitted after Zogenix, Inc. became part of UCB S.A.: 0
Unclear, or no submission date: 0

By the date each study was first submitted to the registry. The registry lists today's sponsor name and keeps no history, so this says when a study was filed, not who filed it.

Status

Completed: 16
Approved for marketing: 1
Active, not recruiting: 1
Terminated: 1

Phase

Phase 1: 8
Phase 3: 4
Phase 2: 3
Phase 4: 1

Where

United States: 9
Germany: 3
Spain: 3
Italy: 3
France: 2
Belgium: 2

Registry sponsor names on this page

Zogenix, Inc.19 studies

Something wrong with this grouping? Tell us on the UCB S.A. page.

Studies

Recruiting first, then most recently updated. Showing 19 of 19. All UCB S.A. studies →

Evaluation of Treatment Satisfaction and Preference for Sumavel DosePro in the Treatment of MigraineCompletedNCT01016834Phase 4
Sponsor listed in the registry: Zogenix, Inc. · First submitted before Zogenix, Inc. became part of UCB S.A.
A Phase 3 Study to Examine the Efficacy and Safety of ZX008 in Subjects With CDKL5 Deficiency Disorder.Active, not recruitingNCT05064878Phase 3
Sponsor listed in the registry: Zogenix, Inc. · First submitted before Zogenix, Inc. became part of UCB S.A.
A Study to Investigate the Long-Term Safety of ZX008 (Fenfluramine Hydrochloride) Oral Solution in Children and Adults With Epileptic Encephalopathy Including Dravet Syndrome and Lennox-Gastaut SyndromeCompletedNCT03936777Phase 3
Sponsor listed in the registry: Zogenix, Inc. · First submitted before Zogenix, Inc. became part of UCB S.A.
European Non-interventional Study on Refractory Epilepsy With Developmental DelayTerminatedNCT04398667
Sponsor listed in the registry: Zogenix, Inc. · First submitted before Zogenix, Inc. became part of UCB S.A.
ZX008 Expanded Access ProtocolApproved for marketingNCT03780127
Sponsor listed in the registry: Zogenix, Inc. · First submitted before Zogenix, Inc. became part of UCB S.A.
A Study on the Effects of Repeat Doses of Intraject® Sumatriptan on Local Site SignsCompletedNCT00620425Phase 1
Sponsor listed in the registry: Zogenix, Inc. · First submitted before Zogenix, Inc. became part of UCB S.A.
Phase 3 Study of Hydrocodone Bitartrate Controlled-release Capsules in Subjects With Chronic Low Back PainCompletedNCT01081912Phase 3
Sponsor listed in the registry: Zogenix, Inc. · First submitted before Zogenix, Inc. became part of UCB S.A.
A Study to Evaluate the Pharmacokinetics and Bioequivalence of Sumatriptan Delivered Via the Intraject SystemCompletedNCT00614029Phase 1
Sponsor listed in the registry: Zogenix, Inc. · First submitted before Zogenix, Inc. became part of UCB S.A.
Pharmacokinetics and Metabolism of Hydrocodone Bitartrate Extended-Release (HC-ER) in Subjects With Renal ImpairmentCompletedNCT02244762Phase 1
Sponsor listed in the registry: Zogenix, Inc. · First submitted before Zogenix, Inc. became part of UCB S.A.
A Safety, Tolerability and Pharmacokinetic Dose Escalation Study of HC-ER in Patients With Osteoarthritis PainCompletedNCT02222740Phase 2
Sponsor listed in the registry: Zogenix, Inc. · First submitted before Zogenix, Inc. became part of UCB S.A.
Pharmacokinetics and Metabolism of Hydrocodone Bitartrate Controlled-Release (HC-CR) in Subjects With Hepatic ImpairmentCompletedNCT02242734Phase 1
Sponsor listed in the registry: Zogenix, Inc. · First submitted before Zogenix, Inc. became part of UCB S.A.
A Safety and PK Study of Injectable Risperidone-SABER and the DosePro Delivery System in Patients With SchizophreniaCompletedNCT01592110Phase 1
Sponsor listed in the registry: Zogenix, Inc. · First submitted before Zogenix, Inc. became part of UCB S.A.
A Study to Determine the Influence of Co-ingestion of Alcohol on Hydrocodone Bitartrate Extended Release (HC-ER)CompletedNCT02126917Phase 1
Sponsor listed in the registry: Zogenix, Inc. · First submitted before Zogenix, Inc. became part of UCB S.A.
A Study on the Usability of the Needle-free Intraject® System in Adult Patients During Acute Migraine AttackCompletedNCT00530517Phase 2
Sponsor listed in the registry: Zogenix, Inc. · First submitted before Zogenix, Inc. became part of UCB S.A.
To Assess the Rate and Extent of Absorption of Hydrocodone From 20 mg Hydrocodone Bitartrate Extended-Release CapsulesCompletedNCT02117141Phase 1
Sponsor listed in the registry: Zogenix, Inc. · First submitted before Zogenix, Inc. became part of UCB S.A.
A Multicenter Active Comparator Study of HC-ER in Adults Following Bunionectomy SurgeryCompletedNCT02197156Phase 2
Sponsor listed in the registry: Zogenix, Inc. · First submitted before Zogenix, Inc. became part of UCB S.A.
A Study on the Intraject Instructions for UseCompletedNCT00619554
Sponsor listed in the registry: Zogenix, Inc. · First submitted before Zogenix, Inc. became part of UCB S.A.
Long-Term Study of Hydrocodone Bitartrate Controlled-release Capsules in Subjects With Chronic PainCompletedNCT01115569Phase 3
Sponsor listed in the registry: Zogenix, Inc. · First submitted before Zogenix, Inc. became part of UCB S.A.
Safety and PK Trial With Injectable ZX003 (Risperidone-SABER®) Compared to Risperdal® Consta® in Stable SchizophreniaCompletedNCT02411526Phase 1
Sponsor listed in the registry: Zogenix, Inc. · First submitted before Zogenix, Inc. became part of UCB S.A.